High induction dosing of risankizumab in patients with moderate-to-severe plaque psoriasis: Interim results from the phase 2 KNOCKOUT study

被引：0
|
作者：
Blauvelt, A. [1 ]
Gudjonsson, J. [2 ]
Matheson, R. [1 ]
Liu, R. [3 ]
Shi, L. [3 ]
Photowala, H. [3 ]
Ehst, B. [1 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Univ Michigan, Dept Dermatol, Sch Med, Ann Arbor, MI USA
[3] AbbVie Inc, N Chicago, IL USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
LB1703
引用
下载
收藏
页码：B16 / B16
页数：1
相关论文
共 50 条
  • [1] Risankizumab in moderate-to-severe plaque psoriasis
    Serrano, Linda
    Maloney, Victoria
    Gordon, Kenneth B.
    IMMUNOTHERAPY, 2019, 11 (16) : 1357 - 1370
  • [2] Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Krueger, James
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate R.
    Visvanathan, Sudha
    Pamulapati, Chandrasena
    Bennett, Nathan
    Flack, Mary
    Scholl, Paul
    Padula, Steven J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16): : 1551 - 1560
  • [3] Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis
    Fioranelli, Massimo
    Roccia, Maria Grazia
    Lotti, Torello
    DERMATOLOGIC THERAPY, 2017, 30 (05)
  • [4] Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Kruger, J. G.
    Tsai, T.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H.
    Paul, C.
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E25
  • [5] Efficacy and safety of continuous risankizumab or switching from adalimumab to risankizumab treatment in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 IMMvent Trial
    Reich, Kristian
    Gooderham, Melinda
    Thaci, Diamant
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB52 - AB52
  • [6] RISANKIZUMAB EFFICACY/SAFETY IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 16-WEEK RESULTS FROM IMMHANCE
    Blauvelt, Andrew
    Papp, Kim A.
    Gooderham, Melinda
    Langley, Richard G.
    Leonardi, Craig
    Lacour, Jean-Philippe
    Philipp, Sandra
    Tyring, Stephen
    Bukhalo, Michael
    Wu, Jashin J.
    Bagel, Jerry
    Frankel, Ellen H.
    Pariser, David
    Flack, Mary
    Scherer, Joseph
    Geng, Ziqian
    Gu, Yihua
    Camez, Anne
    Thompson, Elizabeth H. Z.
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 30 - 30
  • [7] High and durable clearance through 52 weeks of risankizumab treatment in patients with moderate-to-severe plaque psoriasis
    Gooderham, M.
    Lebwohl, M.
    Gordon, K.
    Wu, T.
    Photowala, H.
    Bachelez, H.
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (04) : E30 - E31
  • [8] High and durable clearance through 52 weeks of risankizumab treatment in patients with moderate-to-severe plaque psoriasis
    Gooderham, M.
    Lebwohl, M.
    Gordon, K.
    Wu, T.
    Photowala, H.
    Bachelez, H.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 20 - 20
  • [9] Efficacy and safety of risankizumab (RZB) compared with adalimumab (ADA) in patients with moderate-to-severe plaque psoriasis: results from the phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Krueger, J. G.
    Tsai, T. -F.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H. Z.
    Paul, C.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 : 9 - 10
  • [10] Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
    Ohtsuki, Mamitaro
    Fujita, Hideki
    Watanabe, Mitsunori
    Suzaki, Keiko
    Flack, Mary
    Huang, Xin
    Kitamura, Susumu
    Valdes, Joaquin
    Igarashi, Atsuyuki
    JOURNAL OF DERMATOLOGY, 2019, 46 (08): : 686 - 694
12345